Biotinylated Human TROP-2/TACSTD2 Protein
Catalog No: TROP2-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human TROP-2/TACSTD2 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues His27-Thr274 (UniProt accession: P09758).
Product Details
- Molecular Aliases
- EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2
- Protein Length
- His27-Thr274
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 30.5 kDa. Due to glycosylation, the protein migrates to 46-55 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human TROP-2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human TROP-2 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human TROP-2, His-Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-TROP-2 Antibody, hFc Tag with the EC50 of 3.0ng/ml determined by ELISA (QC Test).
Background
Trop-2,also known as epithelial glycoprotein-1 antigen (EGP-1),is a protein that in humans is encoded by the TACSTD2 gene.Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
References
- Goldenberg D M, Cardillo T M, Govindan S V, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*[J]. Oncotarget, 2015, 6(26).
Have questions about this product?
Our technical team can help with product selection, application questions and order support.